Dihexa
A brain compound aimed at building new connections between neurons. An angiotensin IV analog with strong synaptogenic effect in animal models, often-cited as 'BDNF on steroids.' Very limited human data.
Dihexa: A brain compound aimed at building new connections between neurons. An angiotensin IV analog with strong synaptogenic effect in animal models, often-cited as 'BDNF on steroids.' Very limited human data. Dihexa is a small peptide derived from angiotensin IV.
Dihexa is a small peptide derived from angiotensin IV. In animal studies it dramatically increases brain synaptogenesis, sometimes called 'BDNF on steroids'. Human data is very limited. Treat as experimental and watch the malignancy concern (synaptogenic + growth signal).
Who it's for
- →Users prioritizing cognitive function with experimental tolerance
- →Brain-injury recovery contexts
- →Stack with caution and short cycles
What to expect
- Week 1
Subjective cognitive shifts within days for responders.
- Week 4
Cycle endpoint, limited safety data on chronic use.
- Week 8
Off-cycle. Reassess.
Looking at Dihexa? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for Dihexa.
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account →
How it works (mechanism)
Hexapeptide angiotensin IV analog. Activates the HGF/c-Met signaling pathway with reported synaptogenic effects in animal models. Limited human data on safety or efficacy.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠Active malignancy (theoretical concern)
- ⚠Pregnancy / nursing
- ⚠Anyone risk-averse to early-data peptides
Common mistakes
- • Long cycles without safety data
- • Stacking with multiple experimental nootropics
- • Dismissing the theoretical malignancy concern
What it actually is
Dihexa is a small synthetic molecule derived from angiotensin IV, developed at Washington State University as a potential Alzheimer's treatment. It is usually described as an extremely potent promoter of new synapse formation. It has never been in a human trial: zero human-trial records and zero randomised-trial records are indexed, and the compound has one of the more serious untested risk profiles in this catalog.
Dihexa appears to act by potentiating hepatocyte growth factor and its receptor c-Met, a signalling pathway involved in cell growth, survival and — in the brain — the formation of new synaptic connections. In animal models it improves learning and reverses cognitive deficits, at very low doses. The problem sits in the same sentence: HGF/c-Met is one of the better-known growth and invasion pathways in oncology, which is why the theoretical tumour concern here is specific rather than generic.
Forms, and which is which
It was designed to be orally active and to cross the blood-brain barrier, which is genuinely unusual. No standardised human protocol exists.
Verdict: The route it was designed for, with no human dose behind it.
Requires accurate milligram weighing. No human dose-finding study has been done, so any target is extrapolated.
Verdict: Precise measurement of a number nobody has established.
Combines an untested compound with others, making anything observed unattributable.
Verdict: Several unknowns at once.
Exercise, sleep, hearing correction and cardiovascular risk management have real evidence for cognitive outcomes.
Verdict: The comparison worth making.
What it is claimed to do, graded
Demonstrated in animal and cell models, at strikingly low concentrations. This is the finding the compound's reputation rests on.
Zero human trials of any kind. Grade D on the site's own ladder.
Shown in models including Huntington's and hair-cell protection. Preclinical.
No human safety data at any dose or duration. The specific concern is not vague: potentiating HGF/c-Met signalling is a mechanism directly implicated in tumour growth and invasion.
A marketing phrase, not a finding. It does not act on BDNF, and the comparison has no measured basis.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- • Genuinely novel mechanism, developed in an academic laboratory rather than a marketing one
- • Orally active and crosses the blood-brain barrier, which is rare and was the point of designing it
- • Active at very low concentrations in the animal work
- • Zero human trials — grade D on the site's own ladder
- • The mechanism it works through, HGF/c-Met, is a well-known cancer growth and invasion pathway
- • No human dose-finding study, so every dose circulating was extrapolated
- • No safety data at any duration
- • Sold on a slogan that does not describe what it does
When to stop
- • Any new lump, mole change, or unexplained weight loss
- • Headache or irritability that persists
- • Two to four weeks, on any protocol — nothing supports longer
- • Any new cancer diagnosis, or a family history you had not accounted for
Interactions
HGF/c-Met is directly implicated in tumour growth and metastasis. This is the most specific cancer concern in this catalog, not a formality.
The same pathway concern applies to dormant disease, and nobody has studied it.
Compounds growth signalling with no established benefit.
No interaction data. Nootropic stacking here is entirely uncharacterised.
There is no human interaction literature for this compound at all.
Is this for you?
- • Realistically nobody on the current evidence, given no human data and a mechanism that overlaps directly with cancer biology
- • You have active cancer, a personal cancer history, or a strong family history
- • You are pregnant or nursing
- • You want any human evidence at all
- • You are buying it on the 'BDNF on steroids' description — that is not what it does
The one number
Sources for the claims above
- Hepatocyte growth factor mimetic protects lateral line hair cells
- Effects of an angiotensin IV analog in a Huntington's disease model
- Listed among peptides used outside approved indications
New to Dihexa? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about Dihexa or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week →Frequently asked
What is Dihexa?+
Is Dihexa FDA approved?+
Is Dihexa legal?+
Is Dihexa banned by WADA?+
Are you still natty after taking Dihexa?+
Do doctors prescribe Dihexa?+
What's the typical dose of Dihexa?+
What are the side effects of Dihexa?+
How long until Dihexa starts working?+
What can you stack with Dihexa?+
Where do people get Dihexa?+
Common questions about Dihexa
Tracked alongside Dihexa
Same goal, different aisle — each graded on its own evidence in the Pepdex catalog.
More in Nootropic
The 'bonding hormone' you make naturally. Synthetic oxytocin is FDA-approved for labor; off-label use covers social, anxiety, and intimacy contexts.
A brain-recovery drug used abroad for stroke, head injury, and Alzheimer's. A porcine brain-derived peptide complex used clinically in 50+ countries (Russia, China, Mexico, EU) for stroke recovery, TBI, and Alzheimer's. It's a mixture of low-molecular-weight peptides, not a single compound.
For alertness and focus. A Russian-origin nootropic peptide on the alert/focus end of the spectrum that pairs with Selank for a balanced cognitive stack.
Delta Sleep-Inducing Peptide. A brain-origin peptide aimed at sleep architecture. Limited human data, mixed user reports.